ArticleYonsei medical journal2022
Survey for Government Policies Regarding Strategies for the Commercialization and Globalization of Digital Therapeutics.
Article in Yonsei medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Strategies to Increase Patients' Adherence to Digital Therapeutics for Musculoskeletal Diseases: A Narrative Review.Yonsei medical journal · 2026Review
- Home care program with telemonitoring for patients undergoing peritoneal dialysis in South Korea: a cost-utility analysis.Kidney research and clinical practice · 2025Article
- Willingness to Use and Pay for Telemedicine and Teleconsultation Across Five Clinical Domains in South Korea: Cross-Sectional Survey.Journal of medical Internet research · 2025Article
- A choice based conjoint analysis of mobile healthcare application preferences among physicians, patients, and individuals.NPJ digital medicine · 2025Article
- Insights into insurance coverage for digital therapeutics: A qualitative study of US payer perspectives.Journal of managed care & specialty pharmacy · 2024Article
- Stakeholders' Perceptions Regarding Digital Therapeutics Reimbursement in South Korea: Qualitative Study.JMIR mHealth and uHealth · 2023Article
- Digital therapeutics from bench to bedside.NPJ digital medicine · 2023Article
- A Comparative Study on Intention to Use Digital Therapeutics: MZ Generation and Baby Boomers' Digital Therapeutics Use Intention in Korea.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThis study was conducted to build a direction for government policies regarding strategies for the commercialization of digital therapeutics in Korea, as well as its globalization. MATERIALS AND
methodsThe study included 37 participants from the Korea Digital Health Industry Association (KODHIA). The data was based on a survey conducted in 2020 targeting employees of companies engaged in the digital health industry in Korea. Participants were asked about their involvement in product development of digital therapeutics and their opinion about the growing motivator for digital therapeutics in Korea and the global market.
resultsAccording to our data, among subjects not involved in making digital therapeutics products, the main reason for not being involved was the lack of experts (73.9%) and difficulty in licensing (73.9%). Responses concerning the priority area in need of national support were R&D funding (43.2%), and the next was licensing guidance and simplifying regulations (24.3%). Possible difficulties of overseas market expansion were the unfamiliarity in digital therapeutics technology verification and licensing structures of foreign countries (73%), and concerns regarding the level of recognition of clinical trials and technology in Korea from overseas (70.3%). Overall, respondents were hesitant in starting a related business due to the lack of government support and the complexity of the regulation process. Moreover, concerns about global market entry were similar. Being unfamiliar with the novel process and worrying about the achievement despite existing challenges were the biggest drawback.
conclusionFor the digital therapeutics industry to evolve domestically and internationally, government support and guidance are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.